CAC
BIOSW

Cowen and Company’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

Cowen and Company’s Portfolio BIOSW Stock Details BIOSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-522,096
Closed -$29.2K – 796
2023
Q3 		$29.2K Buy
522,096
+61,109
+13% +$7.31K ﹤0.01% 337
2023
Q2 		$67.9K Buy
460,987
+321,287
+230% +$33.3K 0.01% 257
2023
Q1 		$13.3K Sell
139,700
-38,145
-21% -$3.07K ﹤0.01% 349
2022
Q4 		$17.8K Buy
177,845
+27,895
+19% +$1.43K ﹤0.01% 349
2022
Q3 		$12K Buy
149,950
+100
+0.1% +$11 ﹤0.01% 407
2022
Q2 		$21K Buy
149,850
+55,065
+58% +$10.3K ﹤0.01% 389
2022
Q1 		$22K Buy
+94,785
New +$24.6K ﹤0.01% 426

Cowen and Company's BIOSW Position: Q4 2023 in Review

Cowen and Company sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q4 2023, closing a stake of 522,096 shares — an estimated $29.2K sold.

Cowen and Company first reported a position in BIOSW in Q1 2022 and held it in 7 quarters. The position peaked at $67.9K in Q2 2023. 0 funds tracked by Wall St. Rank hold BIOSW as of Q4 2023.

  • Cowen and Company reported no remaining BioPlus Acquisition Corp. Warrants position as of Q4 2023 after selling out during the quarter.
  • Cowen and Company sold 522,096 BioPlus Acquisition Corp. Warrants shares in Q4 2023, an estimated $29.2K.
  • Cowen and Company first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 7 quarters.
  • Cowen and Company's BioPlus Acquisition Corp. Warrants position peaked at $67.9K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q4 2023.

Based on Cowen and Company's 13F filing for Q4 2023, filed 8 Feb 2024.